{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:07:09Z","timestamp":1779192429825,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1124\/jpet.116.239723","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T01:55:23Z","timestamp":1487037323000},"page":"229-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor"],"prefix":"10.1016","volume":"361","author":[{"given":"Fiona","family":"Elwood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Witter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Piesvaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Kraybill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Bays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Alpert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Goldenblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Ivanovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Sung","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujal V.","family":"Deshmukh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Zielstorff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Byford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalyan","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Dorosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Rivkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Klappenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Sheng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona","family":"Kariv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Dinsmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Slipetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Dandliker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.116.239723_bib1","unstructured":"Ahearn SP, Christopher M, Jung J, Pu Q, Rivkin A, Scott ME, Witter DJ, Woo HC, Cash B, Dinsmore C, et al (2013) inventors, Merck Sharp & Dohme Corporation, assignee. Pyrrolopyrimidines as janus kinase inhibitors. Patent WO 2013085802 A1. 2013 Jun 13."},{"key":"10.1124\/jpet.116.239723_bib2","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/blood.V94.6.1906","article-title":"Reconstitution of early lymphoid proliferation and immune function in Jak3-deficient mice by interleukin-3","volume":"94","author":"Brown","year":"1999","journal-title":"Blood"},{"key":"10.1124\/jpet.116.239723_bib3","unstructured":"Brubaker J, Dinsmore CJ, Hoffman DM, Jung J, Liu D, Peterson S, Siu T, Torres LE, Zhang H, Wei Z, et al. (2013) inventors, Merck Sharp & Dohme Corporation, assignee. Cyanocycloalkyl pyrazole carboxamides as janus kinase inhibitors. Patent WO 2013040863 A1. 2013 Mar 28."},{"key":"10.1124\/jpet.116.239723_bib4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"10.1124\/jpet.116.239723_bib5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"key":"10.1124\/jpet.116.239723_bib6","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/ard.2007.076299","article-title":"Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis","volume":"67","author":"Choy","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/jpet.116.239723_bib7","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.116.239723_bib36","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/jm1004286","article-title":"Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection","volume":"53","author":"Flanagan","year":"2010","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.116.239723_bib11","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1074\/jbc.M114.595181","article-title":"Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol","volume":"290","author":"Goedken","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.116.239723_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.chembiol.2011.01.012","article-title":"Jak1 has a dominant role over Jak3 in signal transduction through gammac-containing cytokine receptors","volume":"18","author":"Haan","year":"2011","journal-title":"Chem Biol"},{"key":"10.1124\/jpet.116.239723_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1124\/jpet.116.239723_bib17","doi-asserted-by":"crossref","first-page":"7334","DOI":"10.1021\/jm200909u","article-title":"Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders","volume":"54","author":"Lim","year":"2011","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.116.239723_bib18","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/art.27536","article-title":"Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice","volume":"62","author":"Lin","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.116.239723_bib19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/nchembio.1666","article-title":"Covalent docking of large libraries for the discovery of chemical probes","volume":"10","author":"London","year":"2014","journal-title":"Nat Chem Biol"},{"key":"10.1124\/jpet.116.239723_bib20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/jpet.114.221176","article-title":"VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease","volume":"353","author":"Mahajan","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.116.239723_bib21","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1124\/jpet.116.239723_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1124\/jpet.116.239723_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bone.2014.11.014","article-title":"Development and optimization of a high-throughput micro-computed tomography imaging method incorporating a novel analysis technique to evaluate bone mineral density of arthritic joints in a rodent model of collagen induced arthritis","volume":"73","author":"Sevilla","year":"2015","journal-title":"Bone"},{"key":"10.1124\/jpet.116.239723_bib25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.116.239723_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1124\/jpet.116.239723_bib27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nchembio.2056","article-title":"Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling","volume":"12","author":"Smith","year":"2016","journal-title":"Nat Chem Biol"},{"key":"10.1124\/jpet.116.239723_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s10875-008-9238-8","article-title":"The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis","volume":"29","author":"Stolina","year":"2009","journal-title":"J Clin Immunol"},{"key":"10.1124\/jpet.116.239723_bib29","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1021\/acs.jmedchem.5b00710","article-title":"Development of selective covalent janus kinase 3 inhibitors","volume":"58","author":"Tan","year":"2015","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.116.239723_bib37","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1124\/jpet.116.239723_bib30","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1016\/j.bmcl.2014.08.046","article-title":"Selective inhibitors of the janus kinase Jak3\u2013are they effective?","volume":"24","author":"Thoma","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.116.239723_bib31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1021\/jm101157q","article-title":"Identification of a potent janus kinase 3 inhibitor with high selectivity within the janus kinase family","volume":"54","author":"Thoma","year":"2011","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.116.239723_bib32","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1021\/cb5002125","article-title":"ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK kinase isoforms to cellular signaling","volume":"9","author":"Thorarensen","year":"2014","journal-title":"ACS Chem Biol"},{"key":"10.1124\/jpet.116.239723_bib33","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1084\/jem.146.3.857","article-title":"Autoimmunity to type II collagen an experimental model of arthritis","volume":"146","author":"Trentham","year":"1977","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.116.239723_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1172\/JCI108929","article-title":"Humoral and cellular sensitivity to collagen in type II collagen-induced arthritis in rats","volume":"61","author":"Trentham","year":"1978","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.116.239723_bib35","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.drudis.2014.03.028","article-title":"Bruton\u2019s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis","volume":"19","author":"Whang","year":"2014","journal-title":"Drug Discov Today"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524195560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524195560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.116.239723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:54:54Z","timestamp":1739980494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524195560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0022356524195560"],"URL":"https:\/\/doi.org\/10.1124\/jpet.116.239723","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.116.239723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}